AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2010
Apr 16, 2010
33651_dirs_2010-04-16_c9260486-591c-4fad-89aa-7c59638a25bc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-04-15
Reporting Person: Varanasi Ramani (VP Business Development)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-04-15 | Stock Option | $4.41 | A | 15000 | Acquired | 2020-04-14 | Common Stock (15000) | Direct |
Footnotes
F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.
F2: Per share.
F3: The options vest in the following increments on the following dates: 937 shares on each of July 15, 2010, January 15, 2011, July 15, 2011, January 15, 2012, July 15, 2012, January 15, 2013, July 15, 2013 and January 15, 2014; and 938 shares vest on each of October 15, 2010, April 15, 2011, October 15, 2011, April 15, 2012, October 15, 2012, April 15, 2013, October 15, 2013, and April 15, 2014, with all such options being fully vested on April 15, 2014.